Kornimate/medical-research-clean huggingface dataset:
a smartphone application for added psychological wellbeing in crohn's disease

Conditions: Crohn Disease

Summary: psychological intervention by cobmindex application to reduce psychological stress among cd patients, fatigue and pain and improve the patients' well being, quality-of-life and disease-coping skills, as well as improvement of the patients' immunological profile and intestinal microbiome.

200 patients will be randomly divided into two groups - 100 patients will learn and practice cobmindex by a human therapist-social worker and 100 patients will learn and practice cobmindex by a digital therapist using the cobmindex application. in the first 3-months there will be an assessment of patient progress following randomization to human therapist or digital therapist using the application for learning and practicing. during this period, the group of the human social-worker will have a limited access to the application dedicated for daily exercises and assessment. in the following 9-month period, all patients will practice using the application, each group by it's permissions. there will be daily assessment of stress, pain, fatigue, well-being and frequent assessments of patients' medical, psychological, and immunological status. throughout the trial, adverse events and concomitant medications will be collected.

Eligibility criteria:
inclusion criteria: * willingness to participate and signed informed consent * hebrew-speaking * age 18-75 * proven diagnosis of crohn's disease, at least 3 months post-diagnosis * stable medical treatment for the last 3 months * any harvey bradshaw index score * ability to operate a smartphone and cellular application exclusion criteria: * diagnosis of ulcerative colitis or unclassified inflammatory bowel disease * planned surgery for crohn's disease * surgery for crohn's disease (excluding drainage of perianal abscess) in the last 3 months * psychiatric disease (schizophrenia, major depression or bipolar disorder) * alcohol or drug dependency (stable medical use of cannabinoids will be allowed) * pregnancy or planned pregnancy during study period * clinically significant comorbidity * former participation in cobmindex trials

Keywords: crohn's disease health related quality of life cognitive behavioral therapy mindfulness immune regulation healthcare cost
assessment of nipple sparing mastectomy as a treatment option for breast cancer

Conditions: Breast Cancer

Summary: nipple-sparing mastectomy (nsm) with immediate breast reconstruction (ibr) is a form of mastectomy that achieves optimal disease control and facilitates reconstruction. the study aimed to assess the oncological safety and aesthetic outcomes of nipple-sparing mastectomy and immediate breast reconstruction. 35 female patients with breast cancer were included in the study. the investigators categorized the incisions into radial, inframammary, and periareolar incisions with planned reconstruction types; direct to implant (dti), transversus rectus abdominis myocutaneous (tram) flap, latissimus dorsi myocutaneous (ld) flap, or ld with implant.


Eligibility criteria:
inclusion criteria: * diagnosis of ductal in situ carcinoma or infiltrating ductal carcinoma with a tumor diameter up to 3 cm * distance of the tumor from the nipple ≥ 2 cm * cancer or microcalcifications not localized in the central field. * no blood secretions or other (nipple-areola complex) nac disturbances * absence of skin involvement * indication to mastectomy for multifocal or diffuse microcalcifications * negative intraoperative assessment of nac-bottom exclusion criteria: * tumor or microcalcifications localized in the central quadrant or in the retroareolar region * blood secretions or other nac alterations * positive intraoperative assessment of nac-bottom * inflammatory carcinoma * paget's disease of the nipple

Keywords: breast cancer mastectomy breast reconstruction
the application of multimodal artificial intelligence systems in prostate cancer diagnosis and prognosis analysis

Conditions: Healthy People; Benign Prostatic Hyperplasia; Prostate Cancer

Summary: the application of multimodal data fusion in prostate cancer will bring new opportunities to improve diagnostic accuracy and treatment outcomes. by integrating imaging, genomics, pathology, and clinical data, we expect to realize precision medicine for prostate cancer and significantly improve the survival prognosis of patients.

prostate cancer stands as one of the most prevalent malignancies among men across the globe. global cancer statistics reveal that the number of new prostate cancer diagnoses rises annually. in recent years, the advent of multimodal data fusion technology has paved the way for innovative diagnostic and prognostic approaches in prostate cancer. for instance, the synergy of mri imaging with clinical indicators such as psa levels and gleason scores not only refines the staging of prostate cancer but also sheds light on a patient's likely response to treatment and survival outlook. the exponential growth of artificial intelligence, particularly the broad adoption of deep learning and machine learning algorithms, has emerged as a formidable asset in the realm of multimodal data analysis. by developing an ai-driven multimodal data fusion system, vast medical datasets can be efficiently processed, laying the groundwork for a more nuanced auxiliary diagnostic and therapeutic decision-making framework.

Eligibility criteria:
inclusion criteria: 1. male, 18-80 years of age; 2. patients with normal prostate, prostatic hyperplasia, or prostate cancer who have undergone a prostate or pelvic magnetic resonance (mr) examination; 3. first visit on january 1, 2014 or later. exclusion criteria: 1. patients with a diagnosis of any other malignancy within the previous 5 years; 2. patients who have undergone transurethral resection or enucleation of the prostate prior to undergoing imaging; 3. patients who are not suitable for participation in this clinical trial in the judgment of the investigator; patients who meet any of the above criteria may not be enrolled as subjects.
feasibility and accuracy of nanosensor-based cancer diagnosis at the point-of-care (chedza)

Conditions: Breast Neoplasms; Lymphoma

Summary: prospective feasibility and validation study of a novel, near-to-care modality for diagnosis of malignancy among cancer suspects.

prospective feasibility and validation study of a novel contrast microhalography (cem) device for diagnosis of malignancy in botswana. consenting patients identified by their providers as requiring a fine needle aspirate (fna) or percutaneous biopsy for assessment for possible lymphoma or breast cancer will undergo standard diagnostic procedure. concurrently these patients will have additional fna fluid tested using the portable novel nanosensor-based device (cem). diagnosis made from standard anatomic pathology, flow cytometry, and/or cytology will be compared with the diagnosis made using the cem platform. assessment of the feasibility and acceptability of the cem platform will be performed. assessment of training requirements for cem platform will be completed.

Eligibility criteria:
inclusion criteria: * botswana citizen * age 18 years or older * able and willing to provide informed consent * undergoing diagnostic procedure for palpable abnormality (biopsy, node/mass resection, or fine-needle aspirate) for diagnosis of possible lymphoid malignancy or breast cancer exclusion criteria: * involuntary incarceration (prison, jail, etc.) * procedures involving internal organs or locations expected to have elevated risk of complication * increased risk for severe bleeding as defined as known hemophilia or other bleeding disorder, use of anticoagulants in past week (not including aspirin or other nsaids), advanced liver disease, or other condition determined by clinician to significantly increase bleeding risk of procedure * known pregnancy * critical illness as defined by current intensive care admission, hypotension (systolic bp\<100mmhg), hypoxemia (o2 saturation \<94% on room air), or other condition determined by clinician to significantly decrease physiologic tolerance of procedure * other condition felt by the clinician performing procedure to significantly increase risk of procedure
anthropometric measures and anti-inflammatory markers by a pufas enriched diet

Conditions: Obesity

Summary: in this work, the investigators report the effects of consume of 15g walnuts and 15g almonds for 8 week on weight, waist and hip circumferences, body mass index, fat mass, serum ldl-cholesterol adiponectin, lipocalin-2 concentration and fatty acids profile.

the study consists of a diet-intervention in a single group under-free-living conditions. the diet was enriched with 15g of almonds and 15g of walnuts per day for eight weeks, supplied directly to the patient by the researcher. this amounts of walnuts and almonds contain polyunsaturated fatty acids of approximately 2.02g of omega 3 (alpha-linolenic acid) and 11.1g of omega 6 (linoleic acid) mostly. in a period of 14 months, the investigators recruited forty-eight sedentary subjects of 30 to 50 years old, and body mass index between 30 and 34.9 kg/m2, without evidence of chronic degenerative, infectious or neoplastic diseases, neither medication nor actually dietary treatment, and a physical level of exercise \< 2 hours/week. all participants gave their written informed consent to participate in the study. the study was approved by the institutional ethics committee of the universidad de guanajuato. collected data included the clinical-nutritional history, 24-hour recalls, and the international physical activity questionnaire was applied to evaluate if subjects were sedentary. the dietary intake evaluation was estimated in kilocalories/day, the amount and type of macronutrients according to the database of united states department of agriculture and the national institute of public health (mexico). in order to evaluate adherence to the diet, volunteers were visited every two weeks to carry out three 24-hour recalls (two on weekdays and one on weekends). positive adherence to the diet plan was considered when the food consumption, walnuts and almonds were not modified more than ± 20% of the amount indicated by the researcher. the investigators recorded the anthropometric measures, body composition, and measured serum glucose, lipid profile, insulin, lipocalin 2, high sensitivity c-reactive protein, adiponectin, and fatty acids profile, which were analyzed at the baseline and after dietary intervention.

Eligibility criteria:
inclusion criteria: - obesity grade i exclusion criteria: * subjects did not have evidence of chronic degenerative, infectious or neoplastic disease. * lack of adherence to the diet and consumption of walnuts and almonds

Keywords: walnuts almonds adiponectin lipocalin-2 obesity
non-interventional study of lenalidomide in the clinical routine treatment of td patients with ipss low or int-1 mds and isolated del(5q)

Conditions: Myelodysplastic Syndrome

Summary: this registry is a prospective, non-interventional, post authorisation safety study for patients diagnosed with transfusion dependent, ipss low or intermediate-1-risk myelodysplastic syndrome (mds), associated to a single abnormality of the chromosome 5 \[del(5q)\]. the purpose of this study is to collect additional data about the safety of an oral drug (lenalidomide, revlimid®) that may have been prescribed to relieve anemia and decrease the need of blood transfusions. however, also patients affected by the mds del(5q) who receive other treatments different from lenalidomide can be included in this study, if they agree.


Eligibility criteria:
inclusion criteria: * are ≥ 18 years old at the time of signing the informed consent form (icf) * are transfusion dependent or have an history of transfusion dependence; for the purpose of the current myelodysplastic syndromes (mds) post-authorization safety study (pass), transfusion-dependence is defined as requiring ≥2 rbc units over an 8 week period prior to the date of signature on the icf (due to mds-related causes and not because of hemorrhage, trauma, or other acute cause) * are on active treatment with lenalidomide (lenalidomide cohort) or have never been exposed to lenalidomide at the time of signing the icf (background cohort) * have confirmed diagnosis of ipss low or intermediate-1-risk mds with isolated del (5q) (with morphological and cytogenetic information) diagnosed on 15 june 2007 (date of revlimid first approved in europe) or later exclusion criteria: * refuse to participate in the myelodysplastic syndromes (mds) post-authorization safety study (pass), * are currently participating in an interventional therapeutic clinical trial for mds (except for erythropoiesis-stimulating agents \[esas\] and granulocyte colonystimulating growth factors) * receive any investigational agent the time of signing the icf * have previously been treated with lenalidomide and are no longer on active treatment with lenalidomide at the time of signing the icf

Keywords: lenalidomide revlimid transfusion-dependent international prognostic scoring system (ipss) low intermediate-1-risk mds isolated del(5q) prospective non-interventional post-authorization safety study (pass) disease registry
acute technical outcomes of the talent abdominal aortic aneurysm (aaa) stent-graft versus cook zenith stent-graft

Conditions: Abdominal Aortic Aneurysm

Summary: the purpose of this study is to compare acute technical outcomes of the talent aaa stent graft system versus cook zenith endograft at two high volume institutions, albany medical center and st. peter's hospital in albany, ny. the investigators are comparing the two devices as part of the evolution of endovascular repair (evar) for aaas. the zenith aaa endovascular graft received fda approval on may 23, 2003, the talent abdominal stent graft system on april 15, 2008.


Eligibility criteria:
inclusion criteria: * subject with abdominal aortic aneurysm, with or without iliac involvement * iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories exclusion criteria: * less than 18 years of age * pregnant or lactating * have contraindications for use of contrast medium or anticoagulation drugs * are patients who have a condition that threatens to infect the graft * are patients with sensitivities or allergies to the device materials

Keywords: patients will be matched based on aaa neck length and neck and iliac angulation
review of medical records of patients who have been treated with lutetium at the cross cancer institute between january 2010 and april 30, 2014

Conditions: Neuroendocrine Tumors, NET

Summary: retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with lutetium-177 dota-tate under health canada's special access programme (sap) at the cross cancer institute between january 2010 and april 30, 2014. efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.


Eligibility criteria:
subjects with neuroendocrine tumours who received lu-177 dota-tate treatment under sap at the cross cancer institute between january 2010 and april 30, 2014.

Keywords: lu-177 lutetium-177 dota-tate neuroendocrine tumors radiopharmaceutical
association between oral lichen planus and thyroid disease

Conditions: Oral Lichen Planus; Thyroid Disease

Summary: the goal of this observational study is to determine the prevalence of thyroid disease in adults with oral lichen planus (olp) treated at the dental hospital of the university of barcelona (houb), and to evaluate the association between olp and thyroid disease. secondly, to assess the association between olp and other comorbidities, including arterial hypertension, diabetes mellitus type 2, dyslipidemia, anxiety, and depression. the main question it aims to answer is: do people with olp have a significant risk of developing thyroid disorders compared to people without olp?

a cross-sectional study was conducted to investigate a total of 120 participants, 60 patients with oral lichen planus and 60 patients without the history of olp as a control group, attending at the dental hospital of the university of barcelona (houb). the personal medical history of thyroid disease, demographic information (age and gender) and other comorbidities history information, were collected in both groups, and obtained through the gesden® healthcare software (gesden g5, infomed - henry schein®, new york, united states), in addition to the paper medical records (biopsy report). data were analyzed using χ² test and simple binary logistic regression models with the spss® statistical software, version 29.0.2.0 for windows (spss, illinois, united states).

Eligibility criteria:
inclusion criteria: * patients over 18 years of age. * for the case group: patients with olp clinically and histologically diagnosed according to the diagnostic criteria of the american academy of oral and maxillofacial pathology. * for the control group: patients without olp lesions, who came to the houb for the treatment of other oral pathologies, and who also do not have a history of clinically and histologically diagnosed olp. exclusion criteria: * patients under 18 years of age. * patients with lichenoid lesions induced by drug reactions or by contact with restorative materials such as amalgam. * patients with complicated or uncontrolled systemic diseases. * patients with other autoimmune diseases (such as systemic lupus erythematosus, sjögren's syndrome, rheumatoid arthritis, psoriasis, celiac disease, vitiligo, diabetes mellitus type 1). * pregnant patients.

Keywords: oral lichen planus thyroid disease thyroid disorders hypothyroidism arterial hypertension dyslipidemia diabetes mellitus depression anxiety association prevalence
safety follow-up study for subjects with agitation associated with dementia of the alzheimer's type who previously participated in a double-blind trial of brexpiprazole or placebo

Conditions: Agitation Associated With Alzheimer's Disease; Alzheimer's Type; Mental Disorder; Nervous System Diseases

Summary: to follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.

behavioral symptoms, such as agitation, are core features in subjects with alzheimer's disease and related dementias, and develop in the majority of dementia subjects. the presence of agitation in subjects with alzheimer's disease places a significant burden not only on subjects and their caregivers but also on the healthcare system. this is a trial designed to assess the ongoing safety of subjects with agitation associated with dementia of the alzheimer's type after completing a 12-week double-blind trial of brexpiprazole or placebo; drug and placebo are discontinued prior to subjects enrolling in the safety follow-up trial. the trial consists of a continuous 2 month observation period. the trial population will include male and female subjects with a diagnosis of probable alzheimer's disease.

Eligibility criteria:
inclusion criteria: * the investigator must assess the capacity of the subject to provide informed consent prior to enrollment and throughout the trial. * male and female subjects who completed both the 12-week double-blind treatment period and the 30-day safety follow-up visit of the previous brexpiprazole trial. * subject has an identified caregiver who is usually assigned to care for the subject on a regular basis, has sufficient contact to describe the subject's symptoms, and has direct observation of the subject's behavior. * subject is able to comply with the protocol requirements. exclusion criterion: * subjects who, in the opinion of the investigator, medical monitor, or sponsor should not participate in the trial.

Keywords: opc-34712 brexpiprazole dementia alzheimer's disease cognitive disorders memory agitation
a prediction model of anastomotic stricture after rectal cancer

Conditions: Colorectal Cancer; Rectal Cancer; Anastomotic Stenosis

Summary: background: anastomotic stricture significantly impacts patients' quality of life and long-term prognosis. however, current clinical practice lacks accurate tools for predicting anastomotic stricture. this study aimed to develop a nomogram to predict anastomotic stricture in patients with rectal cancer who have undergone anterior resection. methods: 1542 eligible patients will be recruited for the study. least absolute shrinkage selection operator (lasso) analysis will be used to preliminarily select predictors. a prediction model will be constructed using multivariate logistic regression and presented as a nomogram. the performance of the nomogram will be evaluated using receiver operating characteristic (roc) curves, calibration diagrams, and decision curve analysis (dca). internal validation will be conducted by assessing the model's performance on a validation cohort.


Eligibility criteria:
inclusion criteria: 1. pathological confirmation of rectal cancer; 2. eligibility for surgical intervention; 3. undergoing first rectal cancer surgery; 4. acquisition of written informed consent from patients and their families; 5. no history of hypertrophic scar or allergic predispositions. exclusion criteria: 1. absence of postoperative follow-up or anastomosis details; 2. patients subjected to hartmann or miles procedures; 3. emergency surgery candidates due to conditions like perforation or obstruction; 4. diagnosis of multiple primary malignancies; 5. intraoperative discovery of widespread implant metastases within the abdominal cavity; 6. severe comorbidities; 7. anastomotic recurrence of rectal cancer; 8. patients who had undergone stapled hemorrhoidopexy

Keywords: nomogram rectal cancer anastomotic stricture